<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>Table 1</label>
 <caption>
  <p>Biological response modifiers discussed.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>BRM class</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Target</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Therapy</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Activity</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>IAV strain</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>References</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Therapeutic antibodies</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HA</td>
    <td valign="top" align="left" rowspan="1" colspan="1">MHAA4549A, MEDI8852 and VIS410</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced viral replication. – Improved symptoms of human patients in phase 2 clinical trials</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Circulating seasonal (2015/16) IAV; Seasonal IAV (H3N2) challenge</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B13" ref-type="bibr">13</xref>–
     <xref rid="B15" ref-type="bibr">15</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">ANGPTL4</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Anti-ANGPTL4</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced pulmonary tissue leakiness, significantly accelerated lung recovery and improved lung tissue integrity in mice.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Mouse-adapted laboratory IAV (H1N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B16" ref-type="bibr">16</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">C5a</td>
    <td valign="top" align="left" rowspan="1" colspan="1">IFX-1 antibody</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced viral load and virus-induced ALI due to reduced infiltration of lung macrophages and neutrophils in IAV-infected African green monkeys.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Highly-pathogenic avian IAV (H7N9)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B17" ref-type="bibr">17</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">TRAIL</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Anti-Trail</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Increased survival rate following IAV infections in mouse studies.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Mouse-adapted laboratory IAV (H1N1 and its derivative H3N2)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B18" ref-type="bibr">18</xref>, 
     <xref rid="B19" ref-type="bibr">19</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">TNFα</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Anti-TNFα</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced disease burden in mouse studies. – No effect on viral replication.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Mouse-adapted laboratory IAV (H1N1-derived H3N2)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B20" ref-type="bibr">20</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Therapeutic peptides</td>
    <td valign="top" align="left" rowspan="1" colspan="1">AMP</td>
    <td valign="top" align="left" rowspan="1" colspan="1">LL-37</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced morbidity and mortality to similar levels as zanamivir in mice.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Mouse-adapted laboratory IAV (H1N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B21" ref-type="bibr">21</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Influenza A virus</td>
    <td valign="top" align="left" rowspan="1" colspan="1">TAT-Kα2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Complete protection of infected mice. – Direct virocidal activity.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Highly-pathogenic avian IAV (H5N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B22" ref-type="bibr">22</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Therapeutic small molecules</td>
    <td valign="top" align="left" rowspan="1" colspan="1">JNK1/JNK2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SP600125, AS601245</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced levels of pro-inflammatory cytokines and reduced viral titers in mice.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Highly-pathogenic avian IAV (H7N7); 2009 pandemic IAV (H1N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B23" ref-type="bibr">23</xref>, 
     <xref rid="B24" ref-type="bibr">24</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">p38</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SB202190, SB203580</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Mice were protected from lethal H5N1 infection exhibiting reduced mortality and pro-inflammatory responses.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Highly-pathogenic avian IAV (H5N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B25" ref-type="bibr">25</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">MEK</td>
    <td valign="top" align="left" rowspan="1" colspan="1">CI-1040</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced lung viral load and mortality of IAV-infected mice.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– 2009 pandemic IAV (H1N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B26" ref-type="bibr">26</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">NFkB</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SC75741</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced mortality and morbidity in mice following highly pathogenic IAV infections. – Similar results prophylactically.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Highly-pathogenic avian IAV (H7N7 and H5N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B27" ref-type="bibr">27</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">GRK2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Paroxetine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Reduced viral load. – No effect on mortality in IAV-infected mice.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– 2009 Pandemic IAV (H1N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B28" ref-type="bibr">28</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">SphK1/SphK2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SK-1I, SK-2I, and Pan-SKI</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Prolonged survival of mice following lethal IAV infection.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Mouse-adapted laboratory IAV (H1N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B29" ref-type="bibr">29</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">PAR1</td>
    <td valign="top" align="left" rowspan="1" colspan="1">SCH79797</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Increased survival and a decrease in inflammatory responses in H5N1 or H1N1 infected mice. – Similar effect when administered 48–72 h after infection.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Mouse-adapted IAVs (H1N1 and H3N2); Oseltamivir-resistant 2009 pandemic IAV isolate (H1N1); highly-pathogenic avian IAV (H5N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B30" ref-type="bibr">30</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">PPARα/PPARγ</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Gemfibrozil (PPARα), Pioglitazone (PPARγ)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– Improved symptoms and increased survival of IAV infected mice. ed survival after H1N1 or H5N1 mouse infections.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">– 1957 Pandemic IAV (H2N2); mouse-adapted laboratory IAV (H1N1); 2009 pandemic IAV (H1N1)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">(
     <xref rid="B31" ref-type="bibr">31</xref>–
     <xref rid="B33" ref-type="bibr">33</xref>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
